scholarly journals Automated diagnosis of atrial fibrillation in 24-hour Holter recording based on deep learning:a study with randomized and real-world data validation

Author(s):  
Peng Zhang ◽  
Fan Lin ◽  
Fei Ma ◽  
Yuting Chen ◽  
Daowen Wang ◽  
...  

SummaryBackgroundWith the increasing demand for atrial fibrillation (AF) screening, clinicians spend a significant amount of time in identifying the AF signals from massive electrocardiogram (ECG) data in long-term dynamic ECG monitoring. In this study, we aim to reduce clinicians’ workload and promote AF screening by using artificial intelligence (AI) to automatically detect AF episodes and identify AF patients in 24 h Holter recording.MethodsWe used a total of 22 979 Holter recordings (24 h) from 22 757 adult patients and established accurate annotations for AF by cardiologists. First, a randomized clinical cohort of 3 000 recordings (1 500 AF and 1 500 non-AF) from 3000 patients recorded between April 2012 and May 2020 was collected and randomly divided into training, validation and test sets (10:1:4). Then, a deep-learning-based AI model was developed to automatically detect AF episode using RR intervals and was tested with the test set. Based on AF episode detection results, AF patients were automatically identified by using a criterion of at least one AF episode of 6 min or longer. Finally, the clinical effectiveness of the model was verified with an independent real-world test set including 19 979 recordings (1 006 AF and 18 973 non-AF) from 19 757 consecutive patients recorded between June 2020 and January 2021.FindingsOur model achieved high performance for AF episode detection in both test sets (sensitivity: 0.992 and 0.972; specificity: 0.997 and 0.997, respectively). It also achieved high performance for AF patient identification in both test sets (sensitivity:0.993 and 0.994; specificity: 0.990 and 0.973, respectively). Moreover, it obtained superior and consistent performance in an external public database.InterpretationOur AI model can automatically identify AF in long-term ECG recording with high accuracy. This cost-effective strategy may promote AF screening by improving diagnostic effectiveness and reducing clinical workload.Research in contextEvidence before this studyWe searched Google Scholar and PubMed for research articles on artificial intelligence-based diagnosis of atrial fibrillation (AF) published in English between Jan 1, 2016 and Aug 1, 2021, using the search terms “deep learning” OR “deep neural network” OR “machine learning” OR “artificial intelligence” AND “atrial fibrillation”. We found that most of the previous deep learning models in AF detection were trained and validated on benchmark datasets (such as the PhysioNet database, the Massachusetts Institute of Technology Beth Israel Hospital AF database or Long-Term AF database), in which there were less than 100 patients or the recordings contained only short ECG segments (30-60s). Our search did not identify any articles that explored deep neural networks for AF detection in large real-world dataset of 24 h Holter recording, nor did we find articles that can automatically identify patients with AF in 24 h Holter recording.Added value of this studyFirst, long-term Holter monitoring is the main method of AF screening, however, most previous studies of automatic AF detection mainly tested on short ECG recordings. This work focused on 24 h Holter recording data and achieved high accuracy in detecting AF episodes. Second, AF episodes detection did not automatically transform to AF patient identification in 24 h Holter recording, since at present, there is no well-recognized criterion for automatically identifying AF patient. Therefore, we established a criterion to identify AF patients by use of at least one AF episode of 6 min or longer, as this condition led to significantly increased risk of thromboembolism. Using this criterion, our method identified AF patients with high accuracy. Finally, and more importantly, our model was trained on a randomized clinical dataset and tested on an independent real-world clinical dataset to show great potential in clinical application. We did not exclude rare or special cases in the real-world dataset so as not to inflate our AF detection performance. To the best of our knowledge, this is the first study to automatically identifies both AF episodes and AF patients in 24 h Holter recording of large real-world clinical dataset.Implications of all the available evidenceOur deep learning model automatically identified AF patient with high accuracy in 24 h Holter recording and was verified in real-world data, therefore, it can be embedded into the Holter analysis system and deployed at the clinical level to assist the decision making of Holter analysis system and clinicians. This approach can help improve the efficiency of AF screening and reduce the cost for AF diagnosis. In addition, our RR-interval-based model achieved comparable or better performance than the raw-ECG-based method, and can be widely applied to medical devices that can collect heartbeat information, including not only the multi-lead and single-lead Holter devices, but also other wearable devices that can reliably measure the heartbeat signals.

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 878-P
Author(s):  
KATHERINE TWEDEN ◽  
SAMANWOY GHOSH-DASTIDAR ◽  
ANDREW D. DEHENNIS ◽  
FRANCINE KAUFMAN

2020 ◽  
Vol 13 ◽  
pp. 175628642092268 ◽  
Author(s):  
Francesco Patti ◽  
Andrea Visconti ◽  
Antonio Capacchione ◽  
Sanjeev Roy ◽  
Maria Trojano ◽  
...  

Background: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. Methods: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan–Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. Results: Time span under observation in the Italian MS Registry was 1–137 (median 80.3) months. In the total Italian patient population ( n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5–39.5) months. Conclusion: CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.


2021 ◽  
Vol 54 (6) ◽  
pp. 1-35
Author(s):  
Ninareh Mehrabi ◽  
Fred Morstatter ◽  
Nripsuta Saxena ◽  
Kristina Lerman ◽  
Aram Galstyan

With the widespread use of artificial intelligence (AI) systems and applications in our everyday lives, accounting for fairness has gained significant importance in designing and engineering of such systems. AI systems can be used in many sensitive environments to make important and life-changing decisions; thus, it is crucial to ensure that these decisions do not reflect discriminatory behavior toward certain groups or populations. More recently some work has been developed in traditional machine learning and deep learning that address such challenges in different subdomains. With the commercialization of these systems, researchers are becoming more aware of the biases that these applications can contain and are attempting to address them. In this survey, we investigated different real-world applications that have shown biases in various ways, and we listed different sources of biases that can affect AI applications. We then created a taxonomy for fairness definitions that machine learning researchers have defined to avoid the existing bias in AI systems. In addition to that, we examined different domains and subdomains in AI showing what researchers have observed with regard to unfair outcomes in the state-of-the-art methods and ways they have tried to address them. There are still many future directions and solutions that can be taken to mitigate the problem of bias in AI systems. We are hoping that this survey will motivate researchers to tackle these issues in the near future by observing existing work in their respective fields.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Albano ◽  
S Nagumo ◽  
M Vanderheyden ◽  
J Bartunek ◽  
C Collet ◽  
...  

Abstract Background Hypothetical concept of disproportionate secondary mitral regurgitation (SMR) has been recently introduced to facilitate patient's selection for mitral valve intervention. However, real world data validating this concept are unavailable. Purpose To investigate long-term effects of minimally invasive mitral valve annuloplasty (MVA) in patients with disproportionate (dSMR) versus proportionate SMR. Methods The study population consisted of 44 consecutive patients (age 67±9,5 years; 64% males) on guidelines-directed therapy with advanced heart failure (HF), reduced LV ejection fraction (EF) (32±9,7%) and SMR undergoing isolated mini-invasive MVA. Patients with organic mitral regurgitation or concomitant myocardial revascularization were excluded. To assess SMR disproportionality, the PISA-derived effective regurgitant orifice area (EROA) and regurgitant volume (RV) were compared to the estimated EROA and RV by using Gorlin formula and pooled real world data. Results According to EROA, a total of 20 (46%) and 24 (54%) patients, respectively, had dSMR and proportionate SMR (pSMR). According to RV, a total of 17 (39%) had dSMR and 27 (61%) had pSMR. Patients with dSMR showed significantly lower prevalence of male gender and higher prevalence of diabetes mellitus than patients with pSMR (p<0,001). Moreover, we observed smaller LV end-diastolic volume, larger EROA and RV (both p<0,01) and higher LV EF (p=0,02) in the dSMR versus the pSMR group. Other baseline characteristics were similar. During median follow up of 4.39 y (IQR 2,2–9,96y), a total of 25 (56%) patients died from any cause while 21 (47%) individuals were readmitted for worsening HF. Patients with dSMR versus pSMR according to both EROA and RV showed significantly lower rate of HF readmissions (both p<0.05) (Figure 1, 2). In Cox regression analysis combining clinical and imaging parameters, dSMR was the only independent predictor of HF readmissions (HR 0.20, 95% CI 0.07–0.60, p=0.004). In contrast, mortality was similar between dSMR and pSMR (NS) with age as the only independent predictor (HR 1,10; 95% CI 1,03–1,18, p=0,003). Conclusions Minimally invasive MVA is associated with significant reduction of HF readmissions in patients with dSMR versus pSMR while the mortality is similar. This suggests the importance of other parameters, i.e. age and degree of LV remodeling, to guide clinical management in SMR. Funding Acknowledgement Type of funding source: None


2021 ◽  
Vol 11 (15) ◽  
pp. 6748
Author(s):  
Hsun-Ping Hsieh ◽  
Fandel Lin ◽  
Jiawei Jiang ◽  
Tzu-Ying Kuo ◽  
Yu-En Chang

Research on flourishing public bike-sharing systems has been widely discussed in recent years. In these studies, many existing works focus on accurately predicting individual stations in a short time. This work, therefore, aims to predict long-term bike rental/drop-off demands at given bike station locations in the expansion areas. The real-world bike stations are mainly built-in batches for expansion areas. To address the problem, we propose LDA (Long-Term Demand Advisor), a framework to estimate the long-term characteristics of newly established stations. In LDA, several engineering strategies are proposed to extract discriminative and representative features for long-term demands. Moreover, for original and newly established stations, we propose several feature extraction methods and an algorithm to model the correlations between urban dynamics and long-term demands. Our work is the first to address the long-term demand of new stations, providing the government with a tool to pre-evaluate the bike flow of new stations before deployment; this can avoid wasting resources such as personnel expense or budget. We evaluate real-world data from New York City’s bike-sharing system, and show that our LDA framework outperforms baseline approaches.


2021 ◽  
Vol 160 (6) ◽  
pp. S-342-S-343
Author(s):  
Nathaniel A. Cohen ◽  
Joshua M. Steinberg ◽  
Alexa Silfen ◽  
Cindy Traboulsi ◽  
Jorie Singer ◽  
...  

2016 ◽  
Vol 116 (10) ◽  
pp. 587-589 ◽  
Author(s):  
Gregory Y. H. Lip ◽  
Ben Freedman

Note: The review process for this manuscript was fully handled by Christian Weber, Editor in Chief.


2021 ◽  
Vol 28 (3) ◽  
pp. 2260-2269
Author(s):  
Daniel Tong ◽  
Lei Wang ◽  
Jeewaka Mendis ◽  
Sharadah Essapen

In the UK, Trifluridine-tipiracil (Lonsurf) is used to treat metastatic colorectal cancer in the third-line setting, after prior exposure to fluoropyrimidine-based regimes. Current data on the real-world use of Lonsurf lack long-term follow-up data. A retrospective evaluation of patients receiving Lonsurf at our Cancer Centre in 2016–2017 was performed, all with a minimum of two-year follow-up. Fifty-six patients were included in the review. The median number of cycles of Lonsurf administered was 3. Median follow-up was 6.0 months, with all patients deceased at the time of analysis. Median progression-free survival (PFS) was 3.2 months, and overall survival (OS) was 5.8 months. The median interval from Lonsurf discontinuation to death was two months, but seven patients received further systemic treatment and median OS gained was 12 months. Lonsurf offered a slightly better PFS but inferior OS to that of the RECOURSE trial, with PFS similar to real-world data previously presented. Interestingly, 12.5% had a PFS > 9 months, and this cohort had primarily left-sided and RAS wild-type disease. A subset received further systemic treatment on Lonsurf discontinuation with good additional OS benefit. Lonsurf may alter the course of disease for a subset of patients, and further treatment on progression can be considered in carefully selected patients.


Sign in / Sign up

Export Citation Format

Share Document